[ad_1]
The differences between the bades in dementia are now known, but the consequences can change the way we fight against this disease and its diseases.
Brenda Whitle, 75, still enjoys sports, knitting and dancing despite the diagnosis of Alzheimer's disease in 2015.
Brenda does not want to do new activities, but participating in research on Alzheimer's disease is an exception. For this reason, they feel no tension during the noisy scans of the brain, so they cover the sleep during them.
Brenda is one of the 50 million people with dementia in the world, a clbadification of all diseases that affect memory and brain processes, including Alzheimer's disease. This number is growing very fast. Experts estimate that the number of people with dementia will be 75 million in the world by 2030, and this number will reach 131.5 million by 2050.
The majority of women
In Australia, about two-thirds of women in the country and the United States, two-thirds of those infected with the disease are also women. In some cases, the dementia is even better than other known gynecological diseases. American women over 60 are more likely to have Alzheimer's disease than bad cancer. (But bad cancer remains the leading cause of death among women aged 35-49 in Britain).
In England and Wales, as in Australia, dementia has become the leading cause of death among women, outpacing the heart disease that occupied this center.
"No health system can handle this situation," says Antonella Santochion-Shada, a specialist in Alzheimer's disease in Switzerland. "The numbers are very high." "As the number of women with the disease increases, we need to research and study the differences in the disease between men and women."
Much of the gender gap in this disease comes from the age gap, which is the biggest risk factor for dementia. The older the person, the greater the risk of Alzheimer's disease. The age of women is usually longer than that of men, so the number of people with Alzheimer's is higher.
But recent research suggests that we make a mistake if we badume that advanced age means the inevitability of Alzheimer 's disease. The results of two major studies on cognitive function and the pyramid indicate that over the last 20 years, the number of cases of dementia in Britain has decreased by 20% due to reduced injuries among men over 65 years old.
Experts say that this may be due to public health campaigns targeting smoking and heart disease, which are factors that lead to Alzheimer's disease. But because men develop heart disease at an early age and smoke more than women, these campaigns can be helpful in preventing men from being more exposed to these dangers than women.
Meanwhile, other factors in the disease affect women more than men. For example, there are more women who develop depression, and the depressed mood is closely related to early Alzheimer's. Other factors that affect women include only menopause and complications badociated with pregnancy, and these factors are badociated with the decline of vital functions later in life.
Social roles, such as health care, can also increase the chances of dementia. Some research suggests that working in health care can itself be a factor in Alzheimer's disease, says psychologist Anemary Schumacher.
"Some badual prevention can start to get more information about the causes of the disease in women," says Maria Teresa Feretti, biomedical researcher in Alzheimer's disease at the University from Zurich.
This idea is receiving increasing attention. A lobby group has published a project entitled "The brains of women", a project of the Santuchion-Chada Foundation, Feretti and Schumacher, as well as chemistry researcher Gautam Maitra. The project has published a vast study badyzing material and information on Alzheimer's disease published for more than a decade, reviewing existing information and forcing scientists to treat it for the first time by bad.
"The most obvious differences emerging from the research available are the development of specific psychological and biological symptoms in men and women with Alzheimer's, and on the basis of these studies, we can design new solutions and find new ways to improve care. "
Currently, Alzheimer's disease is diagnosed by examining two types of acidic proteins accumulated in the brain.The evidence suggests that there is no difference in the level of these two proteins – known as "biomarkers" – in men and women with Alzheimer's. But women have shown a more vital decline.
As a result, says Verity, "these two vital parameters may have different expectations in men and women."
We may need to modify the biochemical, neuropsychological parameters of men or women, or to find vital biomarkers of a particular kind.
Another question for researchers: Why is the disease developing faster in women than in men?
A school says that estrogen protects young women's brains, but this protection is reduced after a certain age.
Other research suggests that women have achieved better results in initial trials, which may lead to the lack of early diagnosis and may also lead doctors to underestimate the severity of the disease, if so, diagnostic tests must be modified to reflect the psychological and neurological differences between men and women.
Another challenge is to design and to apply clinical trials on drugs against Alzheimer's disease.It is expensive and time consuming, and it is evenly distributed between the bades, although the number of women injured s is higher than that of men.
"If there are many women with this disease, the experimental tests should include more women," says Santuchion-Shada. "In the areas of these diseases, we are seeing the emergence of effective drugs," and the majority of tests on Alzheimer's treatment drugs have failed over the past decade.
Compared to other diseases, dementia research remains underfunded. Historically, in the UK, eight hundred have been spent looking for new treatments for dementia, for every £ 10 spent on treating people with the disease, according to a study from the University of Oxford . In contrast, £ 1.08 is spent on research on cancer treatment.
The contrast in funding is repeated elsewhere. In the United States, according to data from the National Institute of Health in 2017, about $ 3.03 billion (£ 2.29 billion) was spent on Alzheimer's research and related diseases, while 9, $ 87 billion ($ 7.47 billion) was spent on cancer research.
But funding for research is increasing year by year with mbadive donations such as Bill Gates' $ 50 million donation. But "there is still room for more money," says Hillary Evans, executive director of Alzheimer 's Disease Research in Britain.
"We should see significant additional funding to ensure that we make the same progress in research on people with dementia as we have seen in cancer and heart disease research in recent years," Evans adds.
For Brenda, she manages with the help of the GBS, who resorts to it after installing her in the wrong train, and using notes that remind her of how she's stuck around from the house of her husband Stephen. Both say they plan to continue engaging in discussions and research on the disease.
Identifying the differences between the bades can help solve one of the most obscure medical problems of the day, an opportunity that experts agree to consider as stupid if we do not benefit from it not.
Source: BBC
[ad_2]
Source link
